Donate Now Get Research Support

Impact

A generation of progress and counting

Since our founding in 1993, we’ve helped SWOG researchers make significant progress against cancer for patients nationwide. 

Advances in standard cancer care.

Patients enrolled.

Years of human lives saved.

Cancer drug approvals

Per year of human life saved.

Clinical trials

Publications

Treatment trials

Biological samples collected

Impact made possible.

For more than 30 years, we’ve worked alongside physicians, scientists, advocates, and other oncology experts to accelerate science and bridge critical gaps in cancer trials. When federal resources fall short, we step to advance research and support the experts who drive it forward. 

Clinical Impact

2024

The SWOG S1826 trial established nivolumab plus AVD chemotherapy as the new standard of care for advanced Hodgkin lymphoma, replacing brentuximab vedotin + AVD with a regimen showing superior progression-free survival and fewer toxic side effects.

Research Impact

2024

By 2024, SWOG-led research had produced 82+ practice-influential trials and contributed to 14 FDA cancer drug approvals—representing over six decades of network-wide research that has fundamentally transformed how cancer is treated worldwide.

Clinical Impact

2023

SWOG trial results published in 2023 demonstrated further improvements in survival outcomes for prostate cancer patients, building on the network’s decades of work in genitourinary oncology.

Research Impact

2022

Hope Foundation and SWOG initiatives broadened cancer clinical trial participation to more than 700 hospitals nationwide, including community cancer centers and VA facilities, dramatically increasing access to cutting-edge research for patients in all settings.

Clinical Impact

2022

SWOG research demonstrated a meaningful improvement in survival for patients with metastatic prostate cancer through advances in treatment sequencing and novel combination therapies, adding to the network’s legacy of extending life for men with advanced disease.

Clinical Impact

2020

The SWOG S1001 trial proved that most patients with limited-stage diffuse large B-cell lymphoma (DLBCL) can safely skip radiation therapy after four cycles of R-CHOP chemotherapy—cutting long-term toxicity without sacrificing cure rates.

Clinical Impact

2020

The RxPONDER trial (S1007) showed that postmenopausal women with hormone receptor-positive, HER2-negative breast cancer and 1–3 positive lymph nodes do not benefit from chemotherapy when their Oncotype DX Recurrence Score is 25 or lower—sparing thousands of women from unnecessary treatment each year.

Training & Mentorship

2018

Hope Foundation-funded early-career investigator and nurse/CRA training programs expanded access to mentorship and research education across the SWOG network, building the next generation of oncology researchers.

Clinical Impact

2018

SWOG S0337 showed that a single intravesical dose of gemcitabine administered immediately after transurethral tumor removal reduces bladder cancer recurrence by approximately 30%—changing urology guidelines worldwide.

Clinical Impact

2014

The POEMS trial (S0230) proved that goserelin (Zoladex) protects ovarian function in premenopausal women receiving chemotherapy for breast cancer—now a standard fertility-protection option for young women undergoing cancer treatment.

Research Impact

2014

SWOG and NCI launched Lung-MAP, a groundbreaking biomarker-driven ‘master protocol’ for lung cancer—a new model for precision medicine clinical trials that tests multiple targeted therapies simultaneously based on a patient’s tumor genetics.

2008

Launch our fellowship program in honor of long-time Group Chair, Dr. Charles A. Coltman, Jr.

Clinical Impact

2004

SWOG S9916 proved that docetaxel combined with estramustine significantly improves survival in men with metastatic prostate cancer—establishing the first chemotherapy regimen proven to extend life in advanced prostate cancer and changing the global standard of care.

Clinical Impact

2003

The landmark Prostate Cancer Prevention Trial (PCPT) showed that finasteride reduces a man’s risk of developing prostate cancer by approximately 25 percent—the largest prostate cancer prevention study ever conducted.

2003

SWOG 9916 proved that docetaxel + estramustine significantly improves survival in metastatic prostate cancer—changing the global standard of care.

Areas of focus

The Hope Foundation for Cancer Research partners with SWOG Cancer Research Network to provide more than $3 million annually in support of oncology research in lung, breast, gastrointestinal, and genitourinary cancers, as well as melanoma, myeloma, leukemia, lymphoma, and rare diseases. We fund critical, need-based research grants, fellowships, training events, physician education, and patient advocacy.

6 active studies open to enrollment or gathering long-term follow up data.

Learn More

7 active studies open to enrollment or gathering long-term follow up data.

Learn More

8 active studies open to enrollment or gathering long-term follow up data.

Learn More

7 active studies open to enrollment or gathering long-term follow up data.

Learn More

Your support fuels every breakthrough

When you give to The Hope Foundation, you’re not donating to an abstract cause—you’re directly funding the studies, people, and ideas extending and improving lives every day. Your contribution helps:

SWOG conducts studies that other groups won’t, or can’t. SWOG’s vast network stretches coast to coast and to 7 other countries. Its study teams investigate the greatest needs for patients today, not for profits down the road.

SWOG’s 20,000+ members have access to training, fellowships, travel support, and competitive grant awards through our programs. We care about supporting investigators now, and keeping them active in research tomorrow.

SWOG trials reach patients from rural Hawaii to metro Detroit and points between and beyond. We fund work to ensure the best and latest care is made available to patients where they live and when they need it most.

Together, we’re changing what’s possible.

Your donation makes a measurable difference—today, tomorrow, and for patients yet to come.

Just $326 funds one life-year of progress.

$100 $326 $500 $1,000 other
Donate to Research